Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current status and future perspectives of multi-modal bacteria-based cancer therapies.

Clinical and translational medicine·2025
Same author

Nanomedicines Targeting Metabolic Pathways in the Tumor Microenvironment: Future Perspectives and the Role of AI.

Metabolites·2025
Same author

The interconnective role of the UPS and autophagy in the quality control of cancer mitochondria.

Cellular and molecular life sciences : CMLS·2025
Same author

Pharmacological and Biological Targeting of FGFR1 in Cancer.

Current issues in molecular biology·2024
Same author

Correction: Dong et al. Smurf1 Suppression Enhances Temozolomide Chemosensitivity in Glioblastoma by Facilitating PTEN Nuclear Translocation. <i>Cells</i> 2022, <i>11</i>, 3302.

Cells·2024
Same author

The effect of carbon nanoparticles vs. immune colloidal gold technique test strips on parathyroid protection in total thyroidectomy: A randomized clinical trial study.

Head & neck·2024
Same journal

Design-Expert Assisted Formulation Development, Optimization, and Evaluation of Selegiline and Biochanin A Loaded Self-Nanoemulsifying Drug Delivery System.

Drug development research·2026
Same journal

Contrastive Learning-Powered Ultrafast Genome-Wide Virtual Screening: The Rise of DrugCLIP.

Drug development research·2026
Same journal

Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget-Directed Anti-Alzheimer Agents.

Drug development research·2026
Same journal

Benzimidazole-Based VEGFR-2 Inhibitors Inspired by Sorafenib: Synthesis, Biological Evaluation, and Mechanistic Insights.

Drug development research·2026
Same journal

Luliconazole Potentiates Efficacy of Miltefosine Against Leishmania donovani.

Drug development research·2026
Same journal

Naphthalene-4H-Chromene Molecular Hybrids as Dual Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease.

Drug development research·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

Nanoplatform-Based Delivery Systems for PROTACs.

Wenbo Che1, Xinlin Wang1, Sijin Chen1

  • 1Advanced Technology Research Institute, State Key Laboratory of Hearing and Balance Science and Key Labora-tory of Molecular Medicine and Biological Diagnosis and Treatment (Ministry of Industry and Information Technol-ogy), Aerospace Center Hospital, Tangshan Research Institute, School of Life Science, Beijing Institute of Technology, Beijing, China.

Drug Development Research
|May 12, 2026
PubMed
Summary
This summary is machine-generated.

Proteolysis Targeting Chimeras (PROTACs) offer targeted protein degradation but face delivery challenges. Nanodelivery platforms enhance PROTAC bioavailability and therapeutic efficiency for clinical applications.

Keywords:
E3 ubiquitin ligasePROTACsTPDnanodelivery systemsstimuli‐responsive nanoplatforms

More Related Videos

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation
06:57

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Published on: August 11, 2018

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Related Experiment Videos

Last Updated: May 13, 2026

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform
08:02

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation
06:57

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Published on: August 11, 2018

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Delivery

Background:

  • Proteolysis Targeting Chimeras (PROTACs) are bifunctional molecules inducing targeted protein degradation via ubiquitination and proteasomal pathways.
  • PROTACs offer advantages like rapid action, sustained efficacy, and high selectivity in targeted protein degradation (TPD).

Purpose of the Study:

  • To address the in vivo delivery challenges of PROTACs, including poor physicochemical properties.
  • To explore nanodelivery platforms as a strategy to enhance PROTAC bioavailability and therapeutic efficiency.

Main Methods:

  • Review of PROTAC structure and mechanism of action.
  • Analysis of PROTAC limitations in in vivo delivery (e.g., molecular weight, membrane permeability, stability).
  • Examination of nanodelivery platforms for overcoming PROTAC delivery hurdles.

Main Results:

  • PROTACs facilitate targeted protein degradation but exhibit unfavorable physicochemical properties hindering in vivo application.
  • Nanodelivery systems show promise in improving PROTAC bioavailability and stability.
  • Enhanced delivery significantly boosts therapeutic efficiency of PROTACs.

Conclusions:

  • Nanodelivery platforms are a key strategy to overcome PROTAC limitations for effective in vivo targeted protein degradation.
  • This approach accelerates the clinical translation and application of PROTAC-based therapeutics.